Overall, 71.8% (61.5% confirmed) of patients had partial responses to either of two dose levels of pumitamig plus ...

Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN027, an independently developed innovative bispecific antibody-drug conjugate (ADC) ...

Since 2015, Dana-Farber researchers have been participating in clinical trials that evaluate the use of bispecific antibodies for patients with non-Hodgkin lymphoma. Three bispecific antibody ...

Dr Rahul Banerjee discusses ASH 2025 and bispecific antibodies in myeloma, including data from MajesTEC-3, IFM2021-01, and IMMUNOPLANT.

DUBLIN--(BUSINESS WIRE)--The "Global Bispecific Antibody Drug Conjugates Clinical Trials, Regulatory Approvals & Future Market Opportunity Outlook 2029" report has been added to ResearchAndMarkets.com ...

Lagging behind the PD-1xVEGF leaders, Crescent has strengthened its hand by licensing Kelun’s integrin beta-6 ...

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Shaji Kumar, MD, Mayo Clinic, highlights linvoseltamab’s dosing regimen, adverse effect profile, and management strategies. He speaks in particular about cytokine release syndrome, which although ...

Dr. Amany Keruakous sat down for an interview with CURE, in which she discussed how bispecific antibodies for multiple ...

Ever since the first bispecific antibody received regulatory approval in 2009, increasingly sophisticated bispecific antibodies have been sought, particularly in cancer research. Bispecific antibodies ...

The bispecific antibodies market offers promising opportunities due to its rising application in personalized medicine for cancers and autoimmune disorders, with significant growth in hematological ...